| 王文博,许 焱,刘凤华,董幼溪,方 静,史振伟.复方α-酮酸联合血液透析和血液灌流治疗慢性肾衰竭的疗效及对钙磷代谢的影响[J].现代生物医学进展英文版,2020,(6):1189-1192. |
| 复方α-酮酸联合血液透析和血液灌流治疗慢性肾衰竭的疗效及对钙磷代谢的影响 |
| Therapeutic Effect of Compound α-ketoacid Combined with Hemodialysis and Hemoperfusion in the Treatment of Chronic Renal Failure and Its Effect on Calcium and Phosphorus Metabolism |
| Received:October 28, 2019 Revised:November 23, 2019 |
| DOI：10.13241/j.cnki.pmb.2020.06.043 |
| 中文关键词: 复方α-酮酸 血液透析 血液灌流 慢性肾衰竭 钙磷代谢 |
| 英文关键词: Compound α-ketoacid Hemodialysis Hemoperfusion Chronic renal failure Calcium and phosphorus metabolism |
| 基金项目:北京市科技计划项目(Z151100004116023) |
| Author Name | Affiliation | E-mail | | WANG Wen-bo | Department of Nephrology, Beijing Emergency General Hospital, Beijing, 100028, China | wangwenbo1006@126.com | | XU Yan | Department of Nephrology, Beijing Emergency General Hospital, Beijing, 100028, China | | | LIU Feng-hua | Department of Nephrology, Beijing Emergency General Hospital, Beijing, 100028, China | | | DONG You-xi | Department of Nephrology, Beijing Emergency General Hospital, Beijing, 100028, China | | | FANG Jing | Department of Nephrology, China Japan Friendship Hospital, Beijing, 100029, China | | | SHI Zhen-wei | Department of Nephrology, Beijing Emergency General Hospital, Beijing, 100028, China | |
|
| Hits: 685 |
| Download times: 465 |
| 中文摘要: |
| 摘要 目的：研究复方α-酮酸联合血液透析和血液灌流治疗慢性肾衰竭（CRF）的临床疗效及对钙磷代谢的影响。方法：选择94例CRF患者为研究对象，按照随机数表法将患者分为联合组与对照组各47例。对照组采用血液透析、血液灌流进行治疗，联合组则在对照组基础之上联合使用复方α-酮酸治疗。比较治疗前及治疗6个月后两组患者肾功能指标[血清胱抑素C（CysC）、血清肌酐（Scr）、血尿素氮（BUN）]及钙磷代谢（血钙、血磷）变化，并分析治疗6个月后两组患者疗效及治疗6个月内药物不良反应发生情况差异。结果：治疗6个月后，联合组治疗总有效率明显高于对照组（P＜0.05）；两组患者CysC、Scr、BUN及血磷水平均较治疗前显著降低，且联合组明显低于同一时间对照组（P＜0.05）。两组患者血钙水平均较治疗前显著升高，且联合组明显高于同一时间对照组（P＜0.05）。治疗6个月内，两组患者药物不良反应总发生率比较差异均无统计学意义（P＞0.05）。结论：复方α-酮酸联合血液透析和血液灌流治疗CRF的疗效显著，且能够改善肾功能与钙磷代谢，对患者疾病转归有利。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of compound α-ketoacid combined with hemodialysis and hemoperfusion in the treatment of chronic renal failure(CRF) and its effect on calcium and phosphorus metabolism. Methods: 94 patients with CRF were selected as subjects, the patients were divided into the combined group and the control group according to the random number table method, each group was 47 cases. The control group was treated with hemodialysis and hemoperfusion, the combined group was treated with compound α-ketoacid in addition to the control group. Renal function indexes of the two groups were compared before and after 6 months of treatment[Cystntinc-C(CysC), Serum creatinine(Scr), Blood Urea Nitrogen(BUN)] and changes in calcium and phosphorus metabolism(blood calcium, blood phosphorus), to analyze the difference between the two groups in the therapeutic effect and the occurrence of adverse drug reactions 6 months after treatment and within 6 months after treatment. Results: After 6 months of treatment, the total effective rate of the combined group was significantly higher than that of the control group(P<0.05). The levels of CysC, Scr, BUN and blood phosphorus in both groups were significantly lower than those before treatment and those in the combined group were significantly lower than the control group at the same time(P<0.05). Blood calcium levels in both groups were significantly higher than before treatment and that in the combined group was significantly higher than the control group at the same time(P<0.05). Within 6 months of treatment, there was no significant difference in the total incidence of adverse drug reactions between the two groups(P>0.05). Conclusion: The therapeutic effect of compound α-ketoacid combined with hemodialysis and hemoperfusion in the treatment of CRF is significant and it can improve renal function, calcium and phosphorus metabolism, it's benefit to the patients' prognosis of disease. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
